Chaligne, Ronan http://orcid.org/0000-0003-4332-3291
Gaiti, Federico http://orcid.org/0000-0001-5111-8816
Silverbush, Dana
Schiffman, Joshua S. http://orcid.org/0000-0002-1028-1438
Weisman, Hannah R.
Kluegel, Lloyd
Gritsch, Simon
Deochand, Sunil D.
Gonzalez Castro, L. Nicolas http://orcid.org/0000-0001-7699-5188
Richman, Alyssa R.
Klughammer, Johanna http://orcid.org/0000-0002-3628-9278
Biancalani, Tommaso
Muus, Christoph
Sheridan, Caroline
Alonso, Alicia
Izzo, Franco http://orcid.org/0000-0002-5813-6504
Park, Jane
Rozenblatt-Rosen, Orit
Regev, Aviv http://orcid.org/0000-0003-3293-3158
SuvĂ , Mario L. http://orcid.org/0000-0001-9898-5351
Landau, Dan A. http://orcid.org/0000-0003-2346-9541
Article History
Received: 9 September 2020
Accepted: 30 July 2021
First Online: 30 September 2021
Competing interests
: M.L.S. is an equity holder, scientific cofounder and advisory board member of Immunitas Therapeutics. A.R. is a founder and equity holder of Celsius Therapeutics, is an equity holder in Immunitas Therapeutics and, until 31 July 2020, was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. Since 1 August 2020, A.R. has been an employee of Genentech. Since 19 October 2020, O.R.-R. has been an employee of Genentech. D.A.L. is an equity holder, scientific cofounder and advisory board member of C2i Genomics and a scientific advisory board member for Mission Bio. The authors declare that these activities are not related to the research reported in this publication and have not influenced the conclusions in this manuscript. The remaining authors declare no competing interests.